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Cell Stem Cell
Editors’ NotesGetting in a State Is Good Sometimes
Two studies in this issue highlight how even quite subtle modifications of growth conditions and media can reap
benefits for stem cell analysis and function. In one, Zeng and Nusse show that adult mouse mammary stem cells
areWnt responsive and that adding purifiedWnt proteinmakes it possible to culture and expand these cells whilemain-
taining their functional capacity, which has not been possible before. Buecker and colleagues, from the Geijsen lab,
instead focused on pluripotent cells, and found that if they generate human iPSCs in the presence of LIF, and with
a generous complement of five reprogramming transcription factors, the reprogrammed cells adopt an altered state
that is much more similar to mouse ESCs than other human ESCs or iPSCs. Strikingly, these mESC-like cells, which
the authors term hLR5 cells, are more amenable to gene targeting, both transgene insertion and homologous recom-tran
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fore be a powerful tool for future research. In an accompanying
preview, Kerr andCheng discuss how these findings relate to other
recent work about different mouse and human pluripotent cell
states. At a broader level, in their Protocol Review, Hasegawa,
Pomeroy, and Pera cover state-of-the-art methods for generating
pluripotent stem cell lines from human embryos, including a focus
on growth conditions.diﬀerenaon to
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Landing on Stepping Stones
This year’s anniversary review feature focuses on strategies for
progressing from basic research to therapeutic application of
stem cell technology. Two groups of authors from organizations focused on laying out roadmaps for translation discuss
their different perspectives on the hurdles that exist and how to tackle them—Trounson and colleagues from California
Institute for Regenerative Medicine and Cuende and Izeta from the Andalusian Initiative for Advanced Therapies. It isunlikely that there will be significant progress without contribution from traditional pharmaceu-
tical companies, and McKernan, McNeish, and Smith from Pfizer Regenerative Medicine
provide their perspective on how cell-based therapies will be integrated into more conventional
drug development pipelines. Despite the broad agreement about the desire to translate find-
ings, there is considerable debate about how, and when, transfer to the clinic should go ahead.
In a Profile article, science writer Anna Davison outlines some of the different views that exist
within the community.
With more of a specific focus on work in this issue, our new Preview-style format, ‘‘In Trans-
lation,’’ discusses the potential clinical applicability of basic stem cell research. The debut
article, from Diehn and Majeti, focuses on a paper from the Wong lab that identifies a CD26+
cell population in colorectal cancer that is associated with distant metastasis. As Diehn and
Majeti discuss, these findings may well be useful both in identifying high-
risk patients (those with a significant CD26+ cell population in their tumor
biopsy) and in devising appropriate therapeutic regimens for them.Tapping into the Chromatin Program
Two papers in this issue provide yetmore evidence for the importance of chro-
matin remodeling in regulating stem cell states. Pereira et al. use a cell-cell
fusion-based system to study the role of PcG proteins in reprogramming to
pluripotency. They found that PRC1 and PRC2 are both required for ESCs
to reprogram a B cell nucleus and, surprisingly, mutant cells are functionally
dominant in a three-way fusion containing a wild-type ESC aswell, suggesting
that lack of PcG function activates the expression of factors that inhibit the
reprogramming process. In a different context, Cherry and Matunis look at the role of nucleosome remodeling factor
(NURF) in the Drosophila germline, and show that it cooperates with JAK-STAT cytokine signaling to maintain germline
and somatic stem cell populations and prevent premature differentiation.Cell Stem Cell 6, June 4, 2010 ª2010 Elsevier Inc. xxi
